Revolution Medicines (RVMD) announced the first patient has been randomized in the RASolute 304 trial. RASolute 304 is a global, open-label, Phase 3 clinical trial evaluating the safety and efficacy of daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with resectable pancreatic ductal adenocarcinoma, PDAC, who have received surgery and chemotherapy. RASolute 304 is anticipated to enroll approximately 500 patients with PDAC harboring oncogenic RAS mutations who have undergone resection and completed perioperative chemotherapy. The trial will assess whether daraxonrasib can improve disease-free survival compared to observation. The primary endpoint in RASolute 304 is disease-free survival, and secondary endpoints include overall survival, safety, and tolerability.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Accelerated Phase 3 Trial and Strong Enrollment Boost Confidence in Revolution Medicines: Buy Rating Affirmed
- Revolution Medicines: Buy Rating Backed by Promising RASolute 302 Trial and Potential Stock Surge
- Strategic Positioning and Potential of Revolution Medicines in Pancreatic Cancer Treatment
- Promising Outlook for Revolution Medicines: Buy Rating Backed by Pivotal Trials and Market Potential
- Revolution Medicines initiated with an Outperform at Wolfe Research